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Background: The role of opioids in the management of chronic neck pain is still poorly inves-
tigated. No data are available on tapentadol extended release (ER). In this article, we present 54 
patients with moderate-to-severe chronic neck pain treated with tapentadol ER.
Patients and methods: Patients received tapentadol ER 100 mg/day; dosage was then 
adjusted according to clinical needs. The following parameters were recorded: pain; Douleur 
Neuropathique 4 score; Neck Disability Index score; range of motion; pain-associated sleep 
interference; quality of life (Short Form [36] Health Survey); Patient Global Impression of 
Change (PGIC); Clinician GIC; opioid-related adverse effects; and need for other analgesics.
Results: A total of 44 of 54 patients completed the 12-week observation. Tapentadol ER daily 
doses increased from 100 mg/day to a mean (standard deviation) dosage of 204.5 (102.8) mg/day 
at the final evaluation. Mean pain intensity at movement significantly decreased from baseline 
(8.1 [1.1]) to all time points (P<0.01). At baseline, 70% of patients presented a positive neu-
ropathic component. This percentage dropped to 23% after 12 weeks. Tapentadol improved 
Neck Disability Index scores from 55.6 (18.6) at baseline to 19.7 (20.9) at the final evaluation 
(P<0.01). Tapentadol significantly improved neck range of motion in all three planes of motion, 
particularly in lateral flexion. Quality of life significantly improved in all Short Form (36) 
Health Survey subscales (P<0.01) and in both physical and mental status (P<0.01). Based on 
PGIC results, approximately 90% of patients rated their overall condition as much/very much 
improved. Tapentadol was well tolerated: no patients discontinued due to side effects. The use 
of other analgesics was reduced during the observed period.
Conclusion: Our results suggest that tapentadol ER, started at 100 mg/day, is effective and 
well tolerated in patients with moderate-to-severe chronic neck pain, including opioid-naïve 
subjects. Patients can expect a decrease in pain, an improvement in neck function, and a decrease 
in neuropathic symptoms.
Keywords: tapentadol, chronic neck pain, neuropathic pain, opioids, Neck Disability Index, 
range of motion
Introduction
Neck pain is a common disabling disease associated with a high socioeconomic burden. 
More than 50% of the middle-aged population show clinical or radiological signs of 
cervical spine disease; however, this condition is often asymptomatic. The estimated 
1-year incidence of neck pain ranges between 10.4% and 21%, mean prevalence in the 
general population is 23%, and it is slightly higher in women in their fifth decade of 
life.1 The prevalence of cervical spine disease increases with age, and a higher incidence 
has been observed in cigarettes smokers, computer workers, or subjects in occupations 
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that require repetitive use of the upper extremities, such as 
violinists and pilots.2,3 The economic burden of neck pain is 
high, due to medical visits, physiotherapy, pharmacological 
and surgical treatments, working days lost, and compensation 
expenditure. Specifically, >40% of patients with neck injuries 
miss >1 week of work/year and are prone to recurrence within 
1 year from the first episode.4
Neck pain may be caused by different conditions that 
compress, irritate, and eventually destroy sensitive struc-
tures, such as the annulus fibrosus, posterior longitudinal 
ligament, and the capsule of the zygapophyseal joints.5 
Cervical radiculopathy, defined as pain radiating along the 
distribution of a cervical nerve root, can arise from “soft 
disk” herniation (compression of the nerve likely leads to 
localized ischemia and nerve damage), cervical spondylo-
sis (degenerative changes of the neural foramen leading to 
bony osteophytes that impinge on the cervical nerve root), 
or both.6 Other causes of neck pain are facet-joint pain (with 
somatic referral to the shoulders, scapula, and upper limb), 
myofascial syndrome (associated with trigger points located 
in the skeletal muscles), or soft-tissue lesions.7 After an 
acute episode, the resolution of neck pain is not necessar-
ily maintained.8 Pain relapses and chronicity are common 
among patients with neck pain and cervical radiculopathy, 
leading to significant impairment in quality of life, activity 
limitation, and disability. The reasons for progressing from 
acute to subacute pain and subsequently to chronic pain are 
still not completely understood, but awareness is growing on 
the role of central sensitization.9,10
Despite the high frequency of cervical disease, few studies 
are currently available on the efficacy of different pharma-
cological treatments for neck pain. Similarly, there is scant 
evidence supporting cervical epidural injections11 and intra-
articular facet-joint injections;12 however, the number of these 
procedures has dramatically increased over the last few years.
The majority of available trials have evaluated the short- 
and long-term efficacy of surgical approaches (anterior 
cervical diskectomy, cervical disk arthroplasty, and posterior 
decompression),13,14 manipulations,15 physical therapies and 
exercise,16 acupuncture,17 and cognitive behavioral therapy.18 
Therefore, most guidelines are focused on nonpharmacologi-
cal treatment of neck pain,19 while the only published recom-
mendations on the pharmacological approach are based on 
expert opinion, with some evidence being extrapolated from 
clinical trials of analgesic drugs for back pain or other mus-
culoskeletal diseases.20 Paracetamol is an effective first-line 
choice for mild-to-moderate neck pain; on the other hand, 
nonsteroidal anti-inflammatory drugs (NSAIDs), despite 
being more effective than placebo,21 are not satisfactory in 
chronic pain conditions. For people with neck pain lasting 
>12 weeks, trial therapy with amitriptyline or gabapentinoids 
should be considered.20,22
Persistent and chronic back pain are indicative of ongo-
ing central sensitization, characterized by phenomena of 
functional and structural neuroplasticity.23 Due to the pau-
city of clinical studies on chronic neck pain, evidence of 
central sensitization is sparse; however, it has been able to 
be clinically observed in a subgroup of patients.24 In these 
conditions, central analgesics may be more appropriate, 
since they target the opioidergic system and the descending 
inhibitory pathways.10 The efficacy of opioids in neck pain 
and/or cervical radiculopathy has been poorly investigated 
to date,25–27 whereas there is evidence supporting their use 
in low-back pain (LBP).28
In particular, tapentadol, the innovative dual therapy 
that acts as a μ-opioid-receptor agonist and norepinephrine-
reuptake inhibitor, is effective in the treatment of moderate–
severe LBP. Tapentadol extended release (ER) is as effective 
as controlled-release oxycodone29 and more effective than 
the oxycodone–naloxone combination in patients with mixed 
back pain presenting a neuropathic component.30 However, no 
studies are available on the use of tapentadol ER in patients 
suffering from neck pain. The aim of this study was to evalu-
ate the efficacy and tolerability of tapentadol ER in patients 
with moderate–severe chronic neck pain.
Patients and methods
Patients
According to the Italian National Health Service and the 
Local Health Unit institutional review board, this case series 
was an observational study of normal clinical practice and 
treatment and did not require formal review or approval. 
In accordance with the local protocols of routine clinical 
practice, tapentadol ER was used in a sample of 54 consecu-
tive patients suffering from chronic neck pain, and written 
informed consent was obtained from all patients, allowing 
anonymous use of their clinical data.
Inclusion criteria were: 1) men and nonpregnant, non-
lactating women ≥18 years old; 2) clinical diagnosis of 
moderate–severe chronic (at least 3 months of history prior 
to screening) neck pain (>4 at movement on a numerical 
rating scale [NRS] of 0–10), unresponsive to step 1 anal-
gesic ladder drugs (nonopioid drugs), or occasional use of 
step 2 opioids for moderate pain (codeine or tramadol); and 
3) cervical degenerative disease, causing axial neck pain or 
radiculopathy.
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Exclusion criteria were: 1) a history of or laboratory 
values reflecting severe renal or hepatic impairment; 2) use 
of monoamine oxidase inhibitors within 14 days prior to 
screening; 3) history of drug abuse; 4) cognitive failure; 5) 
severe psychiatric disorders; 6) cervical degenerative disease, 
causing myelopathy; 7) planned cervical surgery; (8) malig-
nancy or spinal tumor; 9) compression fractures or luxation 
of the cervical column; and 10) spinal infections.
Treatment
Each patient initially received twice-daily oral doses of tapen-
tadol ER 50 mg. During the titration phase, according to our 
clinical practice, at a minimum of 3-day intervals, upward dose 
titration was allowed in increments of twice-daily tapentadol ER 
50 mg. Doses were managed on the basis of clinical response 
to ensure adequate pain relief without dose-limiting toxicity.
For patients on a stable prestudy regimen of nonopioid 
analgesics, such as paracetamol, NSAIDs, or adjuvant drugs 
(such as antidepressants or anticonvulsants), these medica-
tions were continued according to medical judgment if they 
were well tolerated. Prior World Health Organization (WHO) 
step 2 opioids were discontinued. WHO step 2 and step 3 
opioids, except for the study drug, were prohibited during 
the study. Symptomatic drugs (antiemetics and laxatives) and 
corticosteroids were permitted according to clinical needs.
Evaluations
In accordance with our clinical practice, patients were visited 
or contacted by telephone at least once weekly in the first 
month of treatment, in order to monitor therapy and make 
dosage adjustments as needed according to clinical status. 
Data were recorded at baseline before the initiation of treat-
ment (week 0), at weekly intervals for 2 weeks (week 1, 
week 2), and then at 4 weeks (week 4), 8 weeks (week 8), 
and 12 weeks (week 12).
End points
The primary end point of our evaluation was the change in 
average pain intensity from baseline (week 0) to week 12. 
Pain intensity at rest and at movement were monitored using 
patients’ self-reports on an 11-point NRS from 0 (no pain 
at all) to 10 (worst imaginable pain). Secondary end points 
were comprised as follows.
Changes in neuropathic pain symptoms
These were evaluated using the Douleur Neuropathique 
(DN)-4 (score 0–10).31 The DN4 is a screening tool for 
 neuropathic pain consisting of interview questions and physi-
cal tests. If the score is ≥4, the pain is considered neuropathic.
Neck-specific disability
This was measured with the Neck Disability Index (NDI; 
0–100%).32 The NDI is a revised form of the Oswestry Dis-
ability Index. It is a validated ten-section questionnaire that 
measures activity limitations due to neck pain: each section is 
scored 0–5. If one section is missed, the total score is calculated 
on the completed sections only. The original report provided 
scoring intervals for interpretation, as follows: 0–4 (no dis-
ability), 5–14 (mild disability), 15–24 (moderate disability), 
25–34 (severe disability), and above 34 (complete disability).
Neck range of motion
All cervical active range of motion (ROM) measures were 
performed in the upright sitting position. Neck flexion/exten-
sion (range 0°–45°) and neck side-bending (range 0°–45°) 
were measured with an inclinometer by asking the patient to 
flex their head forward and to extend the neck backward as far 
as possible, and to move each ear to its homolateral shoulder. 
Neck rotation (range 0°–80°) was measured with a universal 
goniometer by asking the patient to rotate in each direction as 
far as possible.33 Neck ROM variation from week 0 to week 
12 is presented as a percentage, calculated as: (ROM value at 
week 12 – ROM value at week 0)/ROM maximum value ×100.
Quality of life
Quality of life was valuated using the Short Form (36) 
(SF-36) Health Survey at week 0 and week 12. The SF-3634 is 
a 36-item survey that evaluates eight dimensions of functional 
health and well-being (physical functioning, role – physical, 
bodily pain, general health, vitality, social functioning, role 
– emotional, and mental health), each scored from 0 (“low-
est level of health”) to 100 (“highest level of health”). The 
individual SF-36 item scores were summarized into physical 
and mental health composite scores.
Pain-associated sleep interference
Pain-associated sleep interference (PSI), assessed on an 
11-point NRS ranging from 0 (pain does not interfere with 
sleep) to 10 (pain completely interferes with sleep).
Global Impression of Change
Patient Global Impression of Change (PGIC) and Clinician 
GIC (CGIC) were used to evaluate patients’ global health 
status. The PGIC and CGIC were evaluated at the end of the 
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study (week 12), using a 7-point descriptive scale: very much 
worse, much worse, minimally worse, no change, minimally 
improved, much improved, and very much improved.
Adverse effects
Adverse effects associated with opioid therapy (such as 
nausea and vomiting, drowsiness, confusion, constipation, 
dry mouth, myoclonus, and sweating) were recorded. The 
need for other analgesics, antiemetic agents, and laxatives 
was evaluated as well.
Statistical methods
All data were collected on a web-based platform (IESSS 
[Ibis enhanced spontaneous study system]) specifically 
planned for spontaneous research and analyzed by IBIS 
Informatica (Milan, Italy) using descriptive statistics. 
P<0.05 was considered statistically significant. All analyses 
were performed using SAS 9.4 software (SAS Institute Inc, 
Cary, NC, USA).
Analysis of continuous variables (tapentadol dosing, pain 
intensity at rest, pain intensity on movement, and cervical 
ROM), measured on scheduled visits during the study period, 
was performed using analysis of variance with repeated 
measures without grouping factors and with multiple com-
parisons versus baseline value, adjusting the chosen signifi-
cance level (P=0.05) with the Bonferroni method. Changes 
in quality of life (SF-36) between baseline score and end 
of study score were analyzed using Student’s paired t-test. 
Analysis of discrete variables (DN4 score and NDI) was 
performed using the nonparametric Wilcoxon signed-rank 
test, with comparisons versus baseline value. Analysis of 
frequency of patients with neuropathic pain was performed 
using McNemar’s test.
Results
Study population
The study included 54 patients. Demographic and baseline 
disease characteristics are presented in Table 1. All patients 
were Caucasian, and 64.8% were female (35 of 54). The 
mean (standard deviation [SD]) age was 56.4 (12.1) years, 
with 42 (77.8%) patients aged ≥65 years. In total, 63% (34 
of 54) of patients had a diagnosis of spondyloarthrosis and 
one in three (18 of 54) presented discal herniation.
More than four patients in five (81.5%, 44 of 54) were still 
on treatment at the end of the study. Ten patients  discontinued 
treatment due to protocol violation (n=2), withdrawal of 
consent for any reason (n=3), unsatisfactory analgesia (n=1), 
loss to follow-up (n=3), or other reasons (n=1). No patients 
discontinued due to adverse events. The main analysis popu-
lation thus included 44 patients. Over the study period, mean 
daily doses of tapentadol PR increased from 100 mg/day at 
the beginning of the study to 204.5 (102.8) mg/day at the final 
evaluation. The highest recorded daily dose was 400 mg/day, 
in six (13.6%) patients.
Pain intensity
Mean pain-intensity score at baseline was 6.8 (2.1) at rest and 
8.8 (1.1) at movement. Mean change at week 12 (primary end 
point) was –5.1 (2.3, P<0.01) at rest and –5.9 (2.6, P<0.01) 
on movement. After the first week of treatment, mean pain 
was significantly reduced to 4.7 (2.3, P<0.01) at rest and 6.7 
(2.5, P<0.01) on movement (Figure 1).
Secondary efficacy end points
DN4 mean values significantly decreased from 4.1 (2) at 
baseline to 1.9 (2.1) at week 12 (P<0.01). At baseline, val-
ues were negative (<4) and positive (≥4) for the presence of 
Table 1 Demographic data at baseline (week 0)
Mean/n SD/%
Age (years), mean and SD 56.4 12.1
Age-group, n and %
<65 years 42 77.8
≥65 years 12 22.2
Sex, n and %
Male 19 35.2
Female 35 64.8
Body weight (kg), mean and SD 72.6 13.8
BMI (kg/m2), mean and SD 26.1 4.3
Neck disease, n and %
Spondyloarthrosis 34 63
Cervical stenosis 6 11.1
Discal herniation 18 33.3
Failed surgery 2 3.7
Spondylodiscitis 0
Other 3 5.6
Duration of pain, n and %
3–6 months 26 48.1
>6 months 21 38.9
Missing 7 13
DN4, n and %
<4 14 25.9
≥4 40 74.1
Previous treatment, n and %
Pharmacotherapy 35 64.8
Surgery 2 3.7
Physiotherapy 18 33.3
Abbreviations: SD, standard deviation; BMI, body mass index; DN, neuropathic 
pain.
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 neuropathic pain in 13 (30%) and 31 (70%) patients, respec-
tively. After 12 weeks, only 23% of patients were positive 
(P<0.01 vs baseline) (Figure 2). Mean NDI scores signifi-
cantly improved at all times of evaluation, from 55.6 (18.6) 
at week 0 to 19.7 (20.9) at week 12 (P<0.001) (Figure 3).
Pain-free active neck ROM significantly improved in all 
three planes of motion over the course of the study (P<0.01). 
Pre/posttreatment effect sizes were large for all the outcomes 
(Table 2). Percentage of neck ROM improvement was higher 
for lateral flexion in both sides compared with other planes of 
motion (Figure 4). Significant improvements were observed 
in all SF-36 domain scores from baseline to final evalua-
tion (P<0.01 for all eight scale scores), as well as in both 
SF-36 physical and mental composite scores (all P<0.001) 
(Figures 5 and 6).
Mean PSI significantly decreased from 6.4 (3.1) at base-
line to 1.9 (2.7) at final evaluation. Differences versus base-
line values were statistically significant at all time intervals 
(P<0.01). At the end of the 12 weeks of treatment, 88.6% of 
patients experienced pain-intensity reduction at movement 
of 30% or greater and 68.2% of 50% or greater.
Quality of sleep was significantly improved (P<0.01) 
from the first week of treatment, with 79.5% of patients 
reporting ≥30% reduction in PSI at week 12. With respect 
to PGIC, the percentage of patients who rated their pain as 
“much/very much improved” was 88.6% (39 of 54). At the 
CGIC evaluation, 93.1% (41 of 54) of caregivers rated the 
patients’ overall condition at week 12 as “much/very much 
improved”.
The most common opioid-related adverse events were 
dizziness (13.7%), constipation (9.1%), nausea (7.8%), 
drowsiness (7.8%), and vomiting (3.8%). Some symptoms 
varied in prevalence during the study period (Table 3). The 
incidence of constipation increased from 5.6% at baseline to 
9.1% at week 12. Nausea, vomiting, and drowsiness increased 
at week 1 and week 2, and totally disappeared from week 
4 to week 12 in all patients. Dizziness increased at week 1 
(9.4%) and week 2 (13.7), and progressively decreased to 
2.3% at week 12. No patients reported sweating or dry mouth, 
and only one case of headache at week 2 was recorded. No 
correlation was observed between tapentadol doses and 
incidence of side effects.
Tolerability and concomitant medications
The use of other analgesics was relatively modest at baseline: 
12 (22.2%) patients were using NSAIDs, eleven (20.4%) 
paracetamol, seven (13.0%) anticonvulsants, and three (5.6%) 
antidepressants; six were on (11.1%) step 2 opioids, three 
(5.6%) corticosteroids, and two (3.7%) topical drugs. Most 
patients reduced their use of other analgesics during the study 
period. At week 4, no patients were taking NSAIDs, cortico-
steroids, or step 2 opioids. Paracetamol and anticonvulsants 
were discontinued by nine (81.8%) and two (28.6%) patients, 
respectively (Table 4). Few patients required antiemetics 
Figure 1 Mean and SD pain intensity (11-point NRS) over time (observed-case analysis) at rest and on movement.
Abbreviations: SD, standard deviation; NRS, numeric rating scale.
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(up to 5.7%), and the proportion of patients taking laxatives 
increased from 1.8% at baseline to 6.8% at week 12.
Discussion
Chronic neck pain has a complex etiology. Most patients 
affected present a neuropathic pain component, which is 
 difficult to manage with simple analgesics (paracetamol, 
NSAIDs, and weak opioids).35 The neuropathic pain component 
may have detrimental effects on health-related quality of life; 
therefore, it should be managed by adding adjuvant drugs to 
traditional analgesics or by using drugs able to address different 
components of pain, given their dual mechanism of action.36
Figure 2 Percentage of patients with neuropathic pain 4 score ≥4 from baseline to week 12 (final evaluation).
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Figure 3 Neck Disability Index (NDI; mean and SD) from baseline to week 12 (final evaluation).
Notes: 55.6% (SD 18.6) at baseline; 44.4% (SD 24.1) at week 1; 38.2% (SD 25.9) at week 2; 31.1% (SD 25.2) at week 4; 25.1% (SD 23.2) at week 8; 19.7% (SD 20.9) at week 12.
Abbreviation: SD, standard deviation.
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The current literature on neck pain and cervical radicu-
lopathy is poor in respect of clinical trials on the efficacy 
and tolerability of analgesic drugs, specifically opioids. 
However, in clinical practice, opioids are among the most 
common therapeutic choices, as suggested by two studies 
on the effects of chronic use of these drugs on the outcomes 
of cervical surgery.26,37 Controlled-release oxycodone25 and 
hydromorphone27 have been successfully used in the manage-
ment of chronic neck pain.
However, traditional opioids are not specifically effective 
in neuropathic pain conditions. Conversely, the innovative 
dual-acting drug tapentadol ER was effective in other forms 
of mixed pain, such as LBP with a neuropathic component30 
and cancer pain arising from bone metastases.38 To our knowl-
edge, this is the first report of the efficacy of tapentadol ER in 
patients with chronic moderate–severe neck pain. Tapentadol 
ER is usually associated with better analgesia compared with 
traditional opioids in chronic mixed pain, with a better toler-
ability profile, due to its lower affinity for the μ-opioid receptor.
In this study, tapentadol ER at a mean dosage of 200 mg/day 
was associated with a significant reduction in pain intensity 
from baseline to final evaluation in patients with moderate–
severe chronic neck pain, 90% of whom were opioid-naïve. 
This dosage was lower than that documented (about 300 mg/
day) in other clinical trials on tapentadol ER for patients with 
chronic LBP, with or without a neuropathic pain component.39 
However, in our study, the drug was well tolerated also in 
patients reaching the dosage of 400 mg/day.
Tapentadol ER was effective in reducing the neuropathic 
component, as recorded by the DN4: 70% of enrolled patients 
Figure 4 Percentage of neck ROM variation from baseline to week 12 (final evaluation).
Abbreviation: ROM, range of motion.
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Table 2 Neck ROM at weeks 0 and 12
Neck ROM (normal values) Week 0 Week 12 Pre/postvariation P-value
Mean (SD) % Mean (SD) % %
Flexion (0°–45°) 31.9 (10) 70.9 37.9 (9.3) 84.2 13.3 <0.01
Extension (0°–45°) 24.8 (11) 55.1 37 (9.4) 82.2 27.1 <0.01
Right lateral flexion (0°–45°) 20.4 (9.7) 45.3 36 (6.7) 80 34.7 <0.01
Left lateral flexion (0°–45°) 19.9 (9.2) 44.2 35.8 (6.7) 79.6 35.5 <0.01
Right rotation (0°–80°) 44.7 (17.8) 55.9 64.1 (11.1) 80.1 24.3 <0.01
Left rotation (0°–80°) 46.3 (17.3) 57.9 64.5 (10.5) 80.6 22.7 <0.01
Abbreviations: ROM, range of motion; SD, standard deviation.
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Figure 5 SF-36 physical and mental health and total score from baseline to week 12 (final evaluation).
Note: **P<0.01 baseline–final improvement, paired t-test.
Abbreviation: SF-36, Short Form (36) Health Survey.
** ** **
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Figure 6 SF-36 scores from baseline to week 12 (final evaluation).
Note: **P<0.01 baseline–final improvement, paired t-test.
Abbreviation: SF-36, Short Form (36) Health Survey.
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presented a positive DN4 score at baseline, which significantly 
reduced along the 12 weeks of treatment. The well-known effi-
cacy of tapentadol ER on the neuropathic component of chronic 
pain is related to its ability to potentiate the noradrenergic 
inhibitory system, without activity on the serotonergic pathway, 
which in chronic conditions may also play a pronociceptive role.
Adequate management of patients with chronic pain 
includes the accurate assessment of their symptoms and 
function using validated tools. To this end, we used several 
disease-specific questionnaires for patients with spinal disor-
ders. Neck ROM and the NDI are specifically used to evalu-
ate the outcomes of surgical, physical, and pharmacological 
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Table 4 Frequency of use (%) of other drugs at various time points
Drugs, n (%) Week 0 Week 1 Week 2 Week 4 Week 8 Week 12
Patients, n 54 53 51 48 45 44
NSAIDs, n (%) 12 (22.2) 1 (1.9) 1 (2) 0 0 0
APAP, n (%) 11 (20.4) 3 (5.7) 2 (3.9) 3 (6.2) 3 (6.7) 2 (4.5)
Antidepressants, n (%) 3 (5.6) 4 (7.5) 3 (5.9) 3 (6.2) 3 (6.7) 3 (6.8)
Anticonvulsants, n (%) 7 (13) 6 (11.3) 6 (11.8) 5 (10.4) 5 (11.1) 5 (11.4)
Corticosteroids, n (%) 3 (5.6) 1 (1.9) 0 0 0 0
Topical drugs, n (%) 2 (3.7) 2 (3.8) 2 (3.9) 3 (6.2) 3 (6.7) 3 (6.8)
Step II opioids, n (%) 6 (11.1) 0 0 0 0 0
Antiemetics, n (%) 0 3 (5.7) 2 (3.9) 0 1 (2.2) 0
Laxatives, n (%) 1 (1.8) 1 (1.9) 1 (2) 3 (6.2) 3 (6.7) 3 (6.8)
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; APAP, acetaminophen.
approaches to patients with cervical diseases. Our results 
showed that patients can experience a significant increase in 
neck ROM after 3 months of treatment with tapentadol ER. 
Increased ROM was reported in all three cardinal planes 
of cervical motion. The plane that most improved for neck 
ROM was the coronal (nearly 35% improvement in both 
sides of lateral bending), which was the less conserved at 
baseline (only 45% of residual lateral flexion). This result is in 
accordance with the functional anatomy of the spine. Lateral 
bending is a complex movement, usually coupled with some 
degree of vertebral rotation. During lateral flexion, indeed, 
the dimensions of intervertebral foramina on the ipsilateral 
side are reduced, with potential root compression and related 
neuropathic pain in patients with degenerative changes of the 
spine. On the other side, the lowest ROM gained was in flexion 
in the sagittal plane. However, it should be noted that flexion 
was the better-conserved ROM at baseline (70.9% of maxi-
mum value), while on the same plane extension was reduced 
at baseline by about 45%. In terms of percentage of ROM 
improvement, our results were better than those reported in 
the literature after anterior cervical decompression and fusion, 
in which the greatest ROM gain was <15%.40 Two possible 
explanations for these results are the different samples (surgi-
cal vs nonsurgical patients) and the potential observation that 
pharmacological treatment reduces pain intensity without the 
movement limitation related to cervical fusion.
Tapentadol ER significantly reduced NDI scores (from 55.6 
at week 0 to 19.7 at week 12). These results suggest a reduction 
from complete disability (>34) to moderate disability (range 
15–24). In another study on patients with neck pain treated with 
opioids, success was defined as a 15-point or greater improve-
ment in NDI.26 A decrease in disability suggests that patients 
had improved function and consequently improved quality of 
life. Indeed, in our study tapentadol ER was associated with 
significant improvement n quality of life, as measured by 
the SF-36. Previous studies have shown a strong correlation 
between the NDI and SF-6D, a short version of the SF-36.41,42
Sleep disturbances are a recognized issue in patients 
with chronic pain.43 An indirect evaluation of efficacy of the 
analgesic treatment is represented by improvement in PSI. In 
particular, patients with cervical problems may suffer during 
the night, due to wrong postures, inadequate pillows, and 
poor pain relief. Indeed, sleep quality is one of the ten items 
of the NDI. In our study, PSI significantly improved by a 
mean of 4.5 points, corresponding to 70% of baseline value.
Overall, these results show that tapentadol ER is effec-
tive in managing severe chronic neck pain. Moreover, it was 
well accepted by patients, with a discontinuation rate lower 
Table 3 Opioid-related symptoms at various time points
Opioid-related symptoms, n (%) Week 0 Week 1 Week 2 Week 4 Week 8 Week 12
Patients, n 54 53 51 48 45 44
Nausea, n (%) 2 (3.7) 4 (7.5) 4 (7.8) 1 (2.1) 0 0
Vomiting, n (%) 0 2 (3.8) 1 (2) 0 0 0
Constipation, n (%) 3 (5.6) 3 (5.7) 3 (5.9) 3 (6.2) 4 (8.9) 4 (9.1)
Dry mouth, n (%) 0 0 0 0 0 0
Dizziness, n (%) 1 (1.8) 5 (9.4) 7 (13.7) 2 (4.2) 3 (6.7) 1 (2.3)
Drowsiness, n (%) 0 4 (7.5) 4 (7.8) 1 (2.1) 1 (2.2) 0
Headache, n (%) 0 0 1 (2) 0 0 0
Sweating, n (%) 0 0 0 0 0 0
Other symptoms, n (%) 0 0 0 0 0 0
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than 20%. Based on PGIC results, about 90% of patients 
rated their overall condition as much/very much improved. 
Given the relatively young age of our patients (mean age 
56 years), which included people of working age, chronic use 
of opioids could be concerning, because of their impact on 
driving ability, the well-known risk of tolerance, dose escala-
tion, opioid-induced hyperalgesia, and addiction.44 However, 
tapentadol ER does not affect driving ability in patients on 
stable doses.45 Moreover, compared with traditional μ-opioid 
agonists during postmarketing surveillance, tapentadol ER 
was associated with the lowest risk of abuse.46
Our study is not without its limitations. These include 
the limited sample size, the open-label nature, and the lack 
of an active or placebo comparator. We recognize that in 
pharmacological trials in the field of pain, a large placebo 
response can be observed, which can be estimated as about 
30% of efficacy. However, in our study the size of response 
to tapentadol ER was significantly higher, measured as about 
90% of patients reporting ≥30% reduction.
This study had exploratory purposes; therefore, further 
studies are warranted in order to support this preliminary evi-
dence on the effectiveness and safety of tapentadol ER in this 
indication. However, these findings support the hypothesis that 
patients with neck pain may benefit from tapentadol treatment 
for chronic moderate–severe pain, and adequate analgesia may 
significantly increase their functionality and quality of life.
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